{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:19:01Z","timestamp":1765545541184},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T00:00:00Z","timestamp":1228176000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s10549-008-0248-2","type":"journal-article","created":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T06:35:38Z","timestamp":1228113338000},"page":"77-81","source":"Crossref","is-referenced-by-count":7,"title":["Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant"],"prefix":"10.1007","volume":"117","author":[{"given":"Leilani","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja L.","family":"Konstantinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Rose","family":"Christiaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Paridaens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,2]]},"reference":[{"key":"248_CR1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(89)91741-8","volume":"1","author":"P Neven","year":"1989","unstructured":"Neven P, De Muylder X, Van Belle Y et al (1989) Tamoxifen and the uterus and endometrium. Lancet 1:375. doi: 10.1016\/S0140-6736(89)91741-8","journal-title":"Lancet"},{"key":"248_CR2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1749-6632.1991.tb37890.x","volume":"622","author":"T Fornander","year":"1991","unstructured":"Fornander T, Rutquivist LE, Wilking N (1991) Effects of tamoxifen on the female genital tract. Ann N Y Acad Sci 622:469\u2013476. doi: 10.1111\/j.1749-6632.1991.tb37890.x","journal-title":"Ann N Y Acad Sci"},{"key":"248_CR3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0140-6736(94)92466-X","volume":"343","author":"RP Kedar","year":"1994","unstructured":"Kedar RP, Bourne TH, Powles TJ et al (1994) Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343:1318\u20131321. doi: 10.1016\/S0140-6736(94)92466-X","journal-title":"Lancet"},{"key":"248_CR4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Constantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer. Report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90:1371\u20131388. doi: 10.1093\/jnci\/90.18.1371","journal-title":"J Natl Cancer Inst"},{"key":"248_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/01.cco.0000180434.31991.bf","volume":"17","author":"L Morales","year":"2005","unstructured":"Morales L, Neven P, Paridaens R (2005) Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 17:559\u2013565. doi: 10.1097\/01.cco.0000180434.31991.bf","journal-title":"Curr Opin Oncol"},{"key":"248_CR6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/CCO.0b013e3282f1c523","volume":"19","author":"R Poole","year":"2007","unstructured":"Poole R, Paridaens R (2007) The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review. Curr Opin Oncol 19:564\u2013572","journal-title":"Curr Opin Oncol"},{"key":"248_CR7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2006.09.003","volume":"43","author":"B Thuerlimann","year":"2007","unstructured":"Thuerlimann B, Koeberle D, Senn HJ (2007) Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. Eur J Cancer 43:46\u201352. doi: 10.1016\/j.ejca.2006.09.003","journal-title":"Eur J Cancer"},{"key":"248_CR8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/annonc\/mdi021","volume":"16","author":"L Morales","year":"2005","unstructured":"Morales L, Timmerman D, Neven P et al (2005) Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 16:70\u201374. doi: 10.1093\/annonc\/mdi021","journal-title":"Ann Oncol"},{"key":"248_CR9","first-page":"s22","volume":"14","author":"O Garrone","year":"2003","unstructured":"Garrone O, Mezi S, Occelli M (2003) Reversal of tamoxifen induced endometrial modifications by switching to letrozole in early breast cancer patients: a prospective TVUS study. Ann Oncol 14:s22","journal-title":"Ann Oncol"},{"key":"248_CR10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/humrep\/dei322","volume":"21","author":"S Duffy","year":"2006","unstructured":"Duffy S, Jackson TL, Lansdown M et al (2006) The ATAC (\u2018Arimidex\u2019, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2\u00a0years of treatment. Hum Reprod 21:545\u2013553. doi: 10.1093\/humrep\/dei322","journal-title":"Hum Reprod"},{"key":"248_CR11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1078-0432.CCR-05-0225","volume":"12","author":"B Gerber","year":"2006","unstructured":"Gerber B, Krause A, Reimer T et al (2006) Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 12:1245\u20131250. doi: 10.1158\/1078-0432.CCR-05-0225","journal-title":"Clin Cancer Res"},{"key":"248_CR12","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2006.04.004","volume":"103","author":"G Garuti","year":"2006","unstructured":"Garuti G, Cellani F, Centinaio G et al (2006) Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. Gynecol Oncol 103:599\u2013603. doi: 10.1016\/j.ygyno.2006.04.004","journal-title":"Gynecol Oncol"},{"key":"248_CR13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-006-9285-x","volume":"101","author":"O Markovitch","year":"2007","unstructured":"Markovitch O, Tepper R, Fishman A et al (2007) Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients. Breast Cancer Res Treat 101:185\u2013190. doi: 10.1007\/s10549-006-9285-x","journal-title":"Breast Cancer Res Treat"},{"key":"248_CR14","first-page":"s111","volume":"106","author":"G Bertelli","year":"2007","unstructured":"Bertelli G, Hall E, Ireland E et al (2007) Endometrial status in the Intergroup Exemestane Study (IES) up to 2\u00a0years post-treatment. Breast Cancer Res Treat 106:s111","journal-title":"Breast Cancer Res Treat"},{"key":"248_CR15","doi-asserted-by":"crossref","first-page":"s198","DOI":"10.1016\/S1359-6349(08)70812-7","volume":"6","author":"DG Kieback","year":"2008","unstructured":"Kieback DG, Harbeck N, Bauer W et al (2008) Endometrial safety of cross-over treatment with tamoxifen followed by exemestane. Eur J Cancer 6:s198","journal-title":"Eur J Cancer"},{"key":"248_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CEJ.0b013e32811080ce","volume":"17","author":"MC Boruban","year":"2008","unstructured":"Boruban MC, Altundag K, Kilic GS, Blankstein J (2008) From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 17:133\u2013138","journal-title":"Eur J Cancer Prev"},{"key":"248_CR17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0960-0760(01)00138-8","volume":"79","author":"JFR Robertson","year":"2001","unstructured":"Robertson JFR (2001) Faslodex (ICI 182, 780), a novel estrogen receptor downregulator\u2014future possibilities in breast cancer. J Steroid Biochem Mol Biol 79:209\u2013212. doi: 10.1016\/S0960-0760(01)00138-8","journal-title":"J Steroid Biochem Mol Biol"},{"key":"248_CR18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cncr.21163","volume":"104","author":"A Howell","year":"2005","unstructured":"Howell A, Pippen J, Elledge RM et al (2005) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer 104:236\u2013239. doi: 10.1002\/cncr.21163","journal-title":"Cancer"},{"key":"248_CR19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdl341","volume":"18","author":"L Perey","year":"2007","unstructured":"Perey L, Paridaens R, Hawle H et al (2007) Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21\/00). Ann Oncol 18:64\u201369. doi: 10.1093\/annonc\/mdl341","journal-title":"Ann Oncol"},{"key":"248_CR20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10549-007-9628-2","volume":"109","author":"P Neven","year":"2008","unstructured":"Neven P, Paridaens R, Pelgrims G et al (2008) Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat 109:59\u201365. doi: 10.1007\/s10549-007-9628-2","journal-title":"Breast Cancer Res Treat"},{"key":"248_CR21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ejca.2004.07.035","volume":"41","author":"JF Robertson","year":"2005","unstructured":"Robertson JF, Come SE, Jones SE et al (2005) Endocrine treatment options for advanced breast cancer-the role of fulvestrant. Eur J Cancer 41:346\u2013356. doi: 10.1016\/j.ejca.2004.07.035","journal-title":"Eur J Cancer"},{"key":"248_CR22","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","volume":"26","author":"S Chia","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L et al (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26:1664\u20131670. doi: 10.1200\/JCO.2007.13.5822","journal-title":"J Clin Oncol"},{"key":"248_CR23","first-page":"1031","volume":"5","author":"A Gaducci","year":"2004","unstructured":"Gaducci A, Cosio S, Genazzani AR (2004) Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs 5:1031\u20131044","journal-title":"Curr Opin Investig Drugs"},{"key":"248_CR24","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/sj.bjc.6600644","volume":"87","author":"S Addo","year":"2002","unstructured":"Addo S, Yates RA, Laight A (2002) A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87:1354\u20131359. doi: 10.1038\/sj.bjc.6600644","journal-title":"Br J Cancer"},{"key":"248_CR25","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/S0015-0282(03)00261-9","volume":"79","author":"J Donnez","year":"2003","unstructured":"Donnez J, Vivancos BH, Kudela M et al (2003) A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil Steril 79:1380\u20131389. doi: 10.1016\/S0015-0282(03)00261-9","journal-title":"Fertil Steril"},{"key":"248_CR26","first-page":"577","volume":"29","author":"M Lux","year":"2006","unstructured":"Lux M, Wenkel E, Beckmann K et al (2006) Fulvestrant: a further treatment option for patients with metastatic uterine cancer? Onkologie 29:577\u2013580. doi: 10.1159\/000096541","journal-title":"Onkologie"},{"key":"248_CR27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2005.09.011","volume":"100","author":"MA Hoffman","year":"2006","unstructured":"Hoffman MA, Khan A (2006) Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy. Gynecol Oncol 100:439\u2013441. doi: 10.1016\/j.ygyno.2005.09.011","journal-title":"Gynecol Oncol"},{"key":"248_CR28","unstructured":"World Medical Association (2008) Review of the declaration of Helsinki. http:\/\/www.wma.net"},{"key":"248_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(05)78216-7","volume":"351","author":"P Neven","year":"1998","unstructured":"Neven P, Vergote I (1998) Should tamoxifen users be screened for endometrial lesions? Lancet 351:155\u2013157. doi: 10.1016\/S0140-6736(05)78216-7","journal-title":"Lancet"},{"issue":"suppl. 6","key":"248_CR30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0959-8049(02)00292-7","volume":"38","author":"M Berli\u00e8re","year":"2002","unstructured":"Berli\u00e8re M, Galant C, Charles A et al (2002) Endometrial evaluation is a very important tool in the management of breast cancer patients. Eur J Cancer 38(suppl. 6):67\u201368. doi: 10.1016\/S0959-8049(02)00292-7","journal-title":"Eur J Cancer"},{"key":"248_CR31","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1158\/1078-0432.CCR-06-0897","volume":"12","author":"L Morales","year":"2006","unstructured":"Morales L, Paridaens R, Timmerman D, Neven P (2006) Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology. Clin Cancer Res 12:5603. doi: 10.1158\/1078-0432.CCR-06-0897","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0248-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-0248-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-0248-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:29:03Z","timestamp":1559219343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-0248-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-0248-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,2]]}}}